Several U.S. deadlines for reviewing new drugs have come and gone without a decision from the FDA. Here is a partial list:
Prasugrel, a blood thinner from Eli Lilly and Daiichi Sankyo. A decision was due Sept. 26. The application remains pending.
Promacta, a drug for a clotting disorder. The deadline was Sept. 19. No decision has been made.
For more go here.